摘要
目的研究索拉非尼联合塞来昔布在体外对胆管癌细胞株SK-ChA-1增殖的影响。方法体外培养人胆管癌细胞株SK-ChA-1,通过MTT法检测索拉非尼单用或与塞来昔布联用时对胆管癌细胞株增殖的抑制作用,Western Blot分析索拉非尼单用或与塞来昔布联用时对胆管癌细胞株内多聚ADP核糖聚合酶(PARP)蛋白表达的影响。结果索拉非尼抑制胆管癌细胞株SK-ChA-1的增殖并诱导细胞凋亡。索拉非尼联合塞来昔布协同抑制胆管癌细胞株SK-ChA-1的增殖。塞来昔布使索拉非尼诱导的胆管癌细胞株SK-ChA-1的凋亡增加。结论索拉非尼联合塞来昔布能协同抑制胆管癌细胞株SK-ChA-1的增殖,这与塞来昔布使索拉非尼诱导的细胞凋亡增加有关。
Objective To investigate the effect of sorafenib and celecoxib combination therapy on proliferation of hmnan cholangiocarcinoma （CC） ceils, using the cultured SK - ChA - 1 cell line. Methods Inhibition of SK - ChA - 1 cell proliferation by sorafenib alone and in combination with celecoxib was studied in vitro using the MTT assay. The anti - neoplastic mechanisms of sorafenib alone and in combination with celecoxib were assessed by Western blot detection of changes in the caspase cleavage substrate poly ADP - ribose polymerase （PARP）. Results SK - ChA - 1 cells treated with sorafenib alone showed a dose - dependent growth inhibition and degradation of PARP. Combination treatment with sorafenib and celecoxib synergistically increased the growth inhibition effects and enhanced the degradation of PARP. Conclusion Combination treatment with sorafenib and eelecoxib results in a synergistic anti - proliferative effect in the human CC cell line SK - ChA - 1 ; the addition of celecoxib enhances sorafenib - induced apoptosis.
出处
《临床肝胆病杂志》
CAS
2013年第1期68-71,共4页
Journal of Clinical Hepatology
基金
国家自然科学基金资助项目(81072014)
